Zheng Quan Shi Bao Wang·2025-04-24 09:53Group 1 - The annual American Society of Clinical Oncology (ASCO) meeting is set to showcase a record number of clinical studies from China National Pharmaceutical Group, with 12 oral presentations and 40 innovative results overall [1][2] - Among the highlighted studies, the combination of Bemarituzumab and Anlotinib is particularly notable, with four presentations focusing on its efficacy against PD-L1 positive advanced non-small cell lung cancer (NSCLC) [2][3] - The ASCO meeting will also feature significant data on Anlotinib, which has been involved in nine studies, marking a milestone for domestic innovative drugs [4] Group 2 - The HER2 bispecific antibody ADC, TQB2102, will present its first human study data at ASCO, with no similar products currently on the market [5] - The CCR8 monoclonal antibody, LM108, will also be discussed, highlighting its potential in pancreatic cancer treatment [5] - The ASCO meeting will take place from May 30 to June 3 in Chicago, with over 50 studies from 22 Chinese pharmaceutical companies included in the oral presentation segment [6]